The COVID-19 pandemic continues to drive significant changes to nearly every industry, from real estate to staffing to consumer goods — but it fundamentally changed how consumers view and access healthcare. As the U.S. continues to navigate the pandemic, alongside mixed economic data, supply chain challenges, and labor challenges, what lies ahead for the healthcare industry in 2022? Below, our experts offer their predictions.
Posts by ICR Westwicke
As public health officials discuss whether to call subsequent COVID-19 vaccinations “boosters,” fearing it gives the impression that previous inoculations weren’t effective—some preferred “third dose” or “final dose”—chalk it up to yet another debate about words and nomenclature related to the worst global pandemic in a century.
In the face of a global pandemic, capital markets have (understandably) seen unprecedented behavior over the past two years. With vaccines, rapid testing, and medical research at center stage of every news outlet and publication, the biotech sector has been especially active. There have been major shifts in both buy- and sell-side activities, leaving many companies wondering how to best raise capital as the world finds its new normal. As young and emerging biotech companies look forward, there is growing concern about the current and future state of funding.
Creating a presentation for an audience of investors is a balancing act. On the one hand, there are specific pieces of information that investors want to see in a certain way, and if you don’t provide that information, they’ll wonder what you’re trying to hide. On the other hand, investors see so many presentations every month — hundreds of slides, thousands of charts, and an endless barrage of bullets and sub-bullets — it’s no wonder that so few make a lasting impression.